Intravitreal AdPEDF demonstrates favorable safety, efficacy potential

Article

Favorable Phase I study results have led to the launch of a Phase I/II trial evaluating the efficacy and safety of AdPEDF (GenVec) treatment of exudative AMD, said Timothy Stout, MD, at the World Ophthalmology Congress.

Favorable Phase I study results have led to the launch of a Phase I/II trial evaluating the efficacy and safety of AdPEDF (GenVec) treatment of exudative AMD, said Timothy Stout, MD, at the World Ophthalmology Congress.

AdPEDF is a second-generation adenovector expressing the human pigment epithelium-derived factor (PEDF) gene. In the dose-escalation Phase I trial, 28 patients received a single intravitreal injection of AdPEDF over the dose range of 1 x 106 pu to 1 x 109.5 pu. Eligible patients had severe neovascularization with BCVA of 20/200 or worse, leaking subfoveal choroidal neovascular lesions up to 12 disc areas in size, and were considered as not suitable candidates for other treatments.

The results showed AdPEDF was well tolerated up to the maximum dose tested and did not result in any drug-related serious adverse events, dose-limiting toxicity or endophthalmitis. Mild anterior chamber flare and cells were the most common adverse events related to the treatment but were not dose-related.

"Little can be said about the efficacy of this study as it was not powered to evaluate efficacy endpoints and considering these patients had such advanced disease. However, we did observe changes in visual acuity and retinal appearance at the higher dose that are very encouraging," said Dr. Stout of the Casey Eye Institute/University of Oregon in the United States.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.